November 18, 2015
FDA grants Breakthrough Therapy designation to Avelumab for treating Merkel cell carcinoma
The US Food and Drug Administration (FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough…